Interactions of Cannabis and Amphetamine-Type Stimulants

Abstract

Amphetamine-type stimulants (ATSs) are a large family of substances of abuse, characterized by well-known mood-and performance-enhancing properties. This class encompasses several high-potency stimulants and entactogens, such as the precursor compound d-amphetamine (AMPH), its synthetic N-methylated derivatives methamphetamine (METH) and 3, 4-methylenedioxy-N-methylamphetamine (MDMA, or "ecstasy"), as well as novel designer drugs, based on substituted forms of the natural alkaloid cathinone. ATSs (and in particular METH) are among the most commonly abused substances worldwide, second only to Cannabis sativa; indeed, the rate of concurrent consumption of METH and cannabis has been increasing over the last decade, particularly among adolescents. Anecdotal evidence suggests that marijuana may offset some unpleasant subjective effects of ATSs, such as anxiety and paranoia. Both drugs have been shown to increase schizophrenia vulnerability in young vulnerable individuals, raising the possibility that their concurrent intake may have synergistic effects with respect to the development of psychotic manifestations. In addition, the combination of these two substances may affect their subjective effects and exacerbate their abuse liability. Although current evidence on the neurobiological interactions of cannabis and ATSs remains mostly elusive, initial studies in animal models suggest that the cannabinoid system may play a relevant role in the motivational and addictive properties of ATSs; furthermore, cannabinoids may modify the behavioral effects and even attenuate some untoward long-term consequences of ATSs. In this chapter we review the available evidence on these potential interactions and outline some key mechanisms that may account for the mutual modulatory influence of these substances.

Identifying Herbal Adverse Events From Spontaneous Reporting Systems Using Taxonomic Name Resolution Approach

“…Herbs placed in proximity to pharmaceutical drugs have similar adverse event profile which may have remained unnoticed. For example, the hierarchical clustering shows comparable adverse event profiles as well as potential interaction 51 for Cannabis sativa and amphetamine/ dextroamphetamine. In addition, such data may shed some light into associated or similar mechanisms underlying ADRs and potential medicinal use.…”

Amphetamine-type stimulants: Novel insights into their actions and use patterns

“…The serotonin syndrome is a life-threatening condition that requires immediate medical attention. Medications that can produce a serotonin syndrome when combined with MDMA include commonly prescribed antidepressants, such as selective serotonin reuptake inhibitors, serotonin, and noradrenaline reuptake inhibitors, monoamine oxidase (MAO) inhibitors, antimigraine triptans, some opioid analgesics (fentanyl, tramadol, and dextromethorphan), and the antidepressant buspirone (Table 2) [29][30][31] .…”